Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 02, 2022 07:00 ET | Source: Eliem Therapeutics, Inc.

Eliem Therapeutics Provides ETX-810 Program Update

SEATTLE and CAMBRIDGE, United Kingdom, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for...
July 18, 2022 07:00 ET | Source: Eliem Therapeutics, Inc.

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

Initiating a Phase 1 pharmacokinetics trial of ETX-155 to enable a Phase 2a trial in MDD planned to commence in first quarter of 2023 Sufficient capital expected to fund operations until mid-2024...
July 07, 2022 07:00 ET | Source: Eliem Therapeutics, Inc.

Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022

SEATTLE and CAMBRIDGE, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for...
June 27, 2022 16:01 ET | Source: Eliem Therapeutics, Inc.

Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP)

Topline data from the Phase 2a clinical trial are expected in the third quarter of 2022 Virtual investor event to be held in July 2022 SEATTLE and CAMBRIDGE, United Kingdom, June 27, 2022 (GLOBE...
May 16, 2022 06:10 ET | Source: Eliem Therapeutics, Inc.

Eliem Therapeutics Reports First Quarter Financial and Business Highlights

SEATTLE and CAMBRIDGE, United Kingdom, May 16, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for...
April 25, 2022 07:00 ET | Source: Eliem Therapeutics, Inc.

Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs

Phase 2a clinical trial of ETX-810 in diabetic peripheral neuropathic pain (DPNP) did not achieve the primary endpoint Phase 2a clinical trial evaluating ETX-810 in patients with lumbosacral...
April 05, 2022 07:00 ET | Source: Eliem Therapeutics, Inc.

Eliem Therapeutics Appoints Susan Franks as Senior Vice President and Head of Regulatory Affairs

SEATTLE and CAMBRIDGE, United Kingdom, April 05, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for...
March 21, 2022 07:00 ET | Source: Eliem Therapeutics, Inc.

Eliem Therapeutics to Present at Stifel’s 2022 CNS Days

SEATTLE and CAMBRIDGE, United Kingdom, March 21, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for...
March 07, 2022 16:10 ET | Source: Eliem Therapeutics, Inc.

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial and Business Highlights

Completed dosing in Phase 2a clinical trial of ETX-810 in subjects with diabetic peripheral neuropathic pain; topline data to be presented in 1H 2022 Interim data from Phase 1b clinical trial of...
February 11, 2022 07:00 ET | Source: Eliem Therapeutics, Inc.

Eliem Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

SEATTLE and CAMBRIDGE, United Kingdom, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for...